SQUAWK/NEWS
Account
Account
Menu
Live NewsCategoriesequity

SAB Biotherapeutics, Inc. (SABS) News

Track canonical SquawkNews coverage tagged to SABS, SAB Biotherapeutics, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 1 indexed stories across 1 publication days and is ordered by the same first-publication timeline used by LiveCast.

Symbol SABS Asset equity Sector Markets 90 days 1 Last 3.69 Updated Jun 24, 2026, 06:50 PM UTC Open live news feed
M SABS: Barclays Initiates Overweight Barclays initiates coverage on SAB Biotherapeutics with an Overweight rating and a price target of $13 EQUITY | Jun 24, 2026, 06:50 PM UTC